- CVS Caremark to stop selling tobacco in all store locations
- Bitcoin gains popularity among retailers
- CVS Caremark showcases outreach program to help customers understand health insurance options
- CVS' Merlo: Health reform to benefit business in 2014
- CVS Caremark Q4 results rise to produce record year
MISSOULA, Mont. — A new line of high-functioning compression socks with a flair for fashion is now available, the sock maker has announced.
Vim & Vigr has introduced an inventive and stylish line of knee-high compression socks that help prevent and reduce spider and varicose veins, inhibit swelling and alleviate leg soreness and heaviness, the company stated. The new line of compression socks uses advanced Gradient Pressure knitting technology to increase circulation of freshly oxygenated blood to help keep legs energeized.
“Our ultimate goal at Vim & Vigr is to help more people experience the benefits of compression socks every day,” said Michelle Huie, founder and president of Vim & Vigr. “Many of us have jobs that require us to sit or stand for long periods of time and this can have serious health and energy implications that affect your quality of life. Vim & Vigr breathes life back into your legs but still allows you to express your own personality.”
According to the company, research shows that excessive hours sitting or standing at a time can be harmful to leg circulation and oxygenation. Vim & Vigr’s debut collection offers socks with a compression level of 15-20 mmHg (millimeter per mercury) with graduated pressure that is tightest at the ankle and becomes less so as it continues up the leg. The socks are specially designed with a contoured leg and heel, as well as a soft toe pocket for added comfort. All of Vim & Vigr’s socks will be listed with the Food and Drug Administration.
Vim & Vigr will roll out 12 sock designs made with wool, nylon and cotton into select retailers as well as available for purchase online through VimVigr.com with a MSRP of $29.95.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.